https://www.worldpharmatoday.com Magazine for the C-level Pharma Executives Thu, 19 Feb 2026 08:31:17 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg https://www.worldpharmatoday.com 32 32 https://www.worldpharmatoday.com/news/fda-approves-monthly-rybrevant-faspro-for-egfr-mutated-nsclc/ Thu, 19 Feb 2026 08:31:17 +0000 https://www.worldpharmatoday.com/uncategorized/fda-approves-monthly-rybrevant-faspro-for-egfr-mutated-nsclc/ Johnson & Johnson (J&J) has obtained approval from the US Food and Drug Administration (FDA) for a revised dosing schedule of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), introducing a once-monthly administration option for patients with advanced, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Rybrevant Faspro is used in combination with Lazcluze (lazertinib) and […]

The post FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC first appeared on World Pharma Today.]]> https://www.worldpharmatoday.com/news/astrazeneca-breztri-reports-positive-phase-iii-trial-results/ Tue, 17 Feb 2026 09:31:31 +0000 https://www.worldpharmatoday.com/uncategorized/astrazeneca-breztri-reports-positive-phase-iii-trial-results/ Results from the Phase III KALOS and LOGOS trials evaluating AstraZeneca Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) in patients with uncontrolled asthma have been published in The Lancet Respiratory Medicine, reporting statistically significant and clinically meaningful improvements compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapies. The studies compared Breztri with Symbicort (budesonide/formoterol fumarate or […]

The post AstraZeneca Breztri Reports Positive Phase III Trial Results first appeared on World Pharma Today.]]>